Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals

This phase II trial tests how well remdesivir works for treatment of respiratory syncytial virus (RSV) infection of the upper respiratory tract in patients receiving cellular or bispecific antibody therapy. Cellular or bispecific antibody therapies cause suppression of the immune system, making infections more frequent and reducing the body's ability to fight the infections. RSV infections are one of the most common respiratory infections in immunocompromised individuals and can cause significant pneumonia and even death. Remdesivir is in a class of medications called antivirals. It works by stopping viruses from spreading in the body.

NCT Number	NCT06817889
Lead Sponsor	Fred Hutchinson Cancer Center Collaborators: Gilead Sciences
Conditions	Hematopoietic and Lymphatic System Neoplasm, Autoimmune Disease, Respiratory Syncytial Virus Infection
Enrollment	60 participants
Start Date	2025-12-23
Primary Completion	2027-11-30 (estimated)
Study Completion	2027-11-30 (estimated)
Updated on ClinicalTrials.gov	2026-08-06